APA (7th ed.) Citation

JS, L., S, S., JH, K., HR, K., N, I., T, H., . . . K, N. (2026). Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52. Cancer science, 117(4), 1124. https://doi.org/10.1111/cas.70330

Chicago Style (17th ed.) Citation

JS, Lee, et al. "Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52." Cancer Science 117, no. 4 (2026): 1124. https://doi.org/10.1111/cas.70330.

MLA (9th ed.) Citation

JS, Lee, et al. "Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52." Cancer Science, vol. 117, no. 4, 2026, p. 1124, https://doi.org/10.1111/cas.70330.